---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-003096"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T11:26:58.305096+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anika Q1 revenue up 3% to $37.9M but net loss widens to $10.4M

## Summary
- OA Pain Mgmt rev $22.6M (+8% YoY); Joint Preservation & Restoration rev $13.5M (+11% YoY).
- Net loss ($10.4M) or ($0.71)/share; adjusted net loss ($5.3M) or ($0.36)/share.
- Adj EBITDA ($1.2M) vs +$2.6M in Q1 2022; gross margin 60% (adj 64%).
- FY 2023 rev guidance reaffirmed at $158-163M; $20M share buyback authorized.
- Post-quarter: settled Parcus arbitration, cooperation with Caligan, added director Fischetti.

## SEC filing metadata
- accession: 0001171843-23-003096
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/0001171843-23-003096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/f8k_050923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-003096
- JSON: https://secwatch.observer/filing/0001171843-23-003096.json
- Plain text: https://secwatch.observer/filing/0001171843-23-003096.txt

## Key facts
- Earnings Releases
  Anika Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $37.9 million, net income ($10.4) million, EPS ($0.71) per share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $37.9 million
  - Net income: ($10.4) million
  - EPS: ($0.71) per share
  - Result: reported results
  source text: First Quarter 2023 Financial Summary Revenue in the first quarter of 2023 was $37.9 million, up 3% compared with $36.7 million in the first quarter of 2022. Osteoarthritis (OA) Pain Management 1 revenue of $22.6 million, up 8% Joint Preservation and Restoration revenue of $13.5 million, up 11% Non-Orthopedic 1 revenue of $1.8 million, down 49% Gross margin was 60%, including $1.6 million of non-cash acquisition-related expenses; Adjusted gross margin 2 was 64%. Net loss was ($10.4) million, or ($0.71) per share, which includes the Parcus Medical unitholder arbitration settlement, as well as shareholder activism and other non-recurring corporate costs, compared to net loss of ($2.9) million, or ($0.20) per share, in the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/0001171843-23-003096-index.htm
- Earnings Releases
  Anika Therapeutics, Inc. reported fiscal year 2023 results: revenue between $158 million and $163 million. Guidance reaffirmed.
  - Period: fiscal year 2023
  - Revenue: between $158 million and $163 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Fiscal 2023 Revenue Outlook The Company continues to expect its overall revenue for fiscal year 2023 to be between $158 million and $163 million, representing growth of 1% to 4% compared to 2022, as growth in OA Pain Management and Joint Preservation and Restoration is offset by lower ancillary Non-Orthopedic revenues*.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/0001171843-23-003096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.